Last updated on August 2019

A Pharmacokinetic Study of Ruxolitinib Phosphate Cream in Pediatric Subjects With Atopic Dermatitis

Brief description of study

The purpose of this study is to evaluate the safety, tolerability and the pharmacokinetics (PK) of topical ruxolitinib cream applied to pediatric subjects (age 2 to 17 years) with atopic dermatitis (AD).

Detailed Study Description

Study has been modified to include younger pediatric subjects (age 2 to 11) in four additional cohorts.

Clinical Study Identifier: NCT03257644

Find a site near you

Start Over